Ken Griffin Fibrogen Inc Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$0.33 - $1.26 $12,276 - $46,872	37,200 Added 44.08%	121,600 $48,000
Q2 2024 Aug 14, 2024	SELL	$0.89 - $2.36 $144,892 - $384,208	-162,800 Reduced 65.86%	84,400 $75,000
Q1 2024 May 15, 2024	BUY	$0.73 - $2.73 $134,101 - $501,501	183,700 Added 289.29%	247,200 $580,000
Q4 2023 Feb 14, 2024	SELL	$0.38 - $0.91 $646 - $1,547	-1,700 Reduced 2.61%	63,500 $56,000
Q3 2023 Nov 14, 2023	SELL	$0.79 - $2.83 $330,615 - $1.18 Million	-418,500 Reduced 86.52%	65,200 $56,000
Q2 2023 Aug 14, 2023	BUY	$2.49 - $20.59 $1.06 Million - $8.8 Million	427,300 Added 757.62%	483,700 $1.31 Million
Q1 2023 May 15, 2023	SELL	$15.95 - $25.18 $1.66 Million - $2.62 Million	-103,900 Reduced 64.82%	56,400 $1.05 Million
Q4 2022 Feb 14, 2023	SELL	$13.27 - $17.73 $217,628 - $290,772	-16,400 Reduced 9.28%	160,300 $2.57 Million
Q3 2022 Nov 14, 2022	BUY	$11.4 - $14.6 $323,760 - $414,640	28,400 Added 19.15%	176,700 $2.3 Million

47.1M

387K

672K

Ticker FGEN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 93,741,200
Market Cap $32.8M
Description
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. The company is developing Roxadustat, an oral small molecule inhibitor of hypoxia inducible factor prolyl hydroxylases, which has completed Phase III clinical development for the treatment of anemia in chronic k...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.